New combo therapy for lung cancer passes first safety test

NCT ID NCT01167530

Completed Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested the drug everolimus (RAD001) alongside radiation therapy in 26 people with advanced non-small cell lung cancer that could not be surgically removed. The goal was to find a safe dose and check for side effects. Participants received everolimus weekly or daily before, during, and after radiation, followed by chemotherapy. The study focused on toxicity, not yet on whether the combination improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus (RAD001)
What this could lead to: If successful, this could point toward a safer way to combine targeted therapy with radiation for advanced lung cancer.
What could go wrong: This is a very early phase 1 trial with only 26 participants, focused on safety and dosing. It is not designed to prove the treatment works, and side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED DISEASE NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Institut Gustave Roussy

Villejuif, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.